Saturday, 18 May 2024


Guggenheim downgrades Bolt Biotherapeutics stock amid leading drug halt By

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sharecare, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm “

On Wednesday, Guggenheim Securities adjusted its stance on Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), moving its rating from Buy to Neutral.

The change in rating follows the company’s announcement that it will halt the development of its leading drug candidate, BDC-1001, a decision coinciding with the departure of its CEO and CMO, as well as a significant workforce reduction.

The biotechnology firm, known for its focus on developing immuno-oncology drugs, faced a major setback with the discontinuation of BDC-1001, which targeted the HER2 protein in cancer cells. This move prompted the reassessment of the company’s stock by Guggenheim.

The analyst from Guggenheim noted that alongside the termination of BDC-1001, the leadership changes and the reduction of half of Bolt’s workforce contribute to an uncertain future for the company. With two other drug candidates, BDC-3042 and BDC-4182, still in the pipeline, the firm’s prospects hinge on their progress.

However, the analyst expressed concerns about the potential success of these remaining candidates, citing “low visibility” on their likelihood of achieving positive outcomes.

Bolt Biotherapeutics has not provided a new price target for its shares, following the removal of the previous target by Guggenheim. This decision reflects the heightened uncertainty about the company’s direction and the expected performance of its stock in the market.

The report from Guggenheim underscores a period of transition for Bolt Biotherapeutics, as the company navigates through the challenges of drug development and adjusts its strategy in light of recent developments. Investors are advised to monitor the company’s next steps as it works to advance its remaining product candidates through the development pipeline.

3rd party Ad. Not an offer or recommendation by See disclosure here or
remove ads

InvestingPro Insights

In light of Guggenheim Securities’ recent downgrade of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), investors might find additional context from InvestingPro data and tips helpful. The company’s market capitalization stands at $50.33 million, reflecting a relatively small player in the biotech industry. Despite significant returns of 18.92% over the last week, the company’s long-term profitability remains in question, as evidenced by a negative P/E ratio of -0.73 for the last twelve months as of Q4 2023.

One of the InvestingPro Tips notes that Bolt holds more cash than debt on its balance sheet, which could…

Click Here to Read the Full Original Article at All News…